SIRT3 deficiency exacerbates fatty liver by attenuating the HIF1α-LIPIN 1 pathway and increasing CD36 through Nrf2

dc.contributor.authorBarroso Fernández, Emma
dc.contributor.authorRodríguez-Rodríguez, Rosalía
dc.contributor.authorZarei, Mohammad
dc.contributor.authorPizarro Delgado, Javier
dc.contributor.authorPlanavila Porta, Ana
dc.contributor.authorPalomer Tarridas, Francesc Xavier
dc.contributor.authorVillarroya i Gombau, Francesc
dc.contributor.authorVázquez Carrera, Manuel
dc.date.accessioned2020-10-06T08:20:15Z
dc.date.available2020-10-06T08:20:15Z
dc.date.issued2020-09-10
dc.date.updated2020-10-06T08:20:15Z
dc.description.abstractBackground: Deficiency of mitochondrial sirtuin 3 (SIRT3), a NAD+ -dependent protein deacetylase that maintains redox status and lipid homeostasis, contributes to hepatic steatosis. In this study, we investigated additional mechanisms that might play a role in aggravating hepatic steatosis in Sirt3-deficient mice fed a high-fat diet (HFD). Methods: Studies were conducted in wild-type (WT) and Sirt3−/− mice fed a standard diet or a HFD and in SIRT3- knockdown human Huh-7 hepatoma cells. Results: Sirt3−/− mice fed a HFD presented exacerbated hepatic steatosis that was accompanied by decreased expression and DNA-binding activity of peroxisome proliferator-activated receptor (PPAR) α and of several of its target genes involved in fatty acid oxidation, compared to WT mice fed the HFD. Interestingly, Sirt3 deficiency in liver and its knockdown in Huh-7 cells resulted in upregulation of the nuclear levels of LIPIN1, a PPARα co-activator, and of the protein that controls its levels and localization, hypoxia-inducible factor 1α (HIF-1α). These changes were prevented by lipid exposure through a mechanism that might involve a decrease in succinate levels. Finally, Sirt3−/− mice fed the HFD showed increased levels of some proteins involved in lipid uptake, such as CD36 and the VLDL receptor. The upregulation in CD36 was confirmed in Huh-7 cells treated with a SIRT3 inhibitor or transfected with SIRT3 siRNA and incubated with palmitate, an effect that was prevented by the Nrf2 inhibitor ML385. Conclusion: These findings demonstrate new mechanisms by which Sirt3 deficiency contributes to hepatic steatosis
dc.format.extent13 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec703469
dc.identifier.issn1478-811X
dc.identifier.pmid32912335
dc.identifier.urihttps://hdl.handle.net/2445/171056
dc.language.isoeng
dc.publisherBioMed Central
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1186/s12964-020-00640-8
dc.relation.ispartofCell Communication and Signaling, 2020, vol. 18, num. 147
dc.relation.urihttps://doi.org/10.1186/s12964-020-00640-8
dc.rightscc-by (c) Barroso Fernández, Emma et al., 2020
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)
dc.subject.classificationMalalties del fetge
dc.subject.classificationLípids
dc.subject.otherLiver diseases
dc.subject.otherLipids
dc.titleSIRT3 deficiency exacerbates fatty liver by attenuating the HIF1α-LIPIN 1 pathway and increasing CD36 through Nrf2
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
703469.pdf
Mida:
2.62 MB
Format:
Adobe Portable Document Format